Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations

Conclusion: The results suggested that treatment with FDC AML/OM was associated with greater likelihood of adherence and lower overall costs than with FDC AML/BEN and LDC AML/ARB, and lower risk of cardiovascular event composite versus LDC AML/ARB.
Source: Therapeutic Advances in Cardiovascular Disease - Category: Cardiology Authors: Tags: Original Research Source Type: research